Japanese Society for Cancer of the Colon and Rectum (JS']JSCCR) guidelines 2016 for the treatment of colorectal cancer

被引:690
作者
Watanabe, Toshiaki [1 ]
Muro, Kei [2 ]
Ajioka, Yoichi [3 ]
Hashiguchi, Yojiro [4 ]
Ito, Yoshinori [5 ]
Saito, Yutaka [6 ]
Hamaguchi, Tetsuya [7 ]
Ishida, Hideyuki [8 ]
Ishiguro, Megumi [9 ]
Ishihara, Soichiro [1 ]
Kanemitsu, Yukihide [10 ]
Kawano, Hiroshi [11 ]
Kinugasa, Yusuke [12 ]
Kokudo, Norihiro [13 ]
Murofushi, Keiko [14 ]
Nakajima, Takako [15 ]
Oka, Shiro [16 ]
Sakai, Yoshiharu [17 ]
Tsuji, Akihito [18 ]
Uehara, Keisuke [19 ]
Ueno, Hideki [20 ]
Yamazaki, Kentaro [21 ]
Yoshida, Masahiro [22 ]
Yoshino, Takayuki [23 ]
Boku, Narikazu [7 ]
Fujimori, Takahiro [24 ]
Itabashi, Michio [25 ]
Koinuma, Nobuo [26 ]
Morita, Takayuki [27 ]
Nishimura, Genichi [28 ]
Sakata, Yuh [29 ]
Shimada, Yasuhiro [30 ]
Takahashi, Keiichi [31 ]
Tanaka, Shinji [32 ]
Tsuruta, Osamu [33 ]
Yamaguchi, Toshiharu [34 ]
Yamaguchi, Naohiko [35 ]
Tanaka, Toshiaki [1 ]
Kotake, Kenjiro [36 ]
Sugihara, Kenichi [37 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Niigata Univ, Grad Sch Med & Dent Sci, Div Mol & Diagnost Pathol, Niigata, Japan
[4] Teikyo Univ, Dept Surg, Tokyo, Japan
[5] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan
[6] Natl Canc Ctr, Endoscopy Div, Tokyo, Japan
[7] Natl Canc Ctr, Div Gastrointestinal Med Oncol, Tokyo, Japan
[8] Saitama Med Univ, Dept Digest Tract & Gen Surg, Saitama Med Ctr, Saitama, Japan
[9] Tokyo Med & Dent Univ, Dept Translat Oncol, Grad Sch, Tokyo, Japan
[10] Natl Canc Ctr, Colorectal Surg Div, Tokyo, Japan
[11] St Marys Hosp, Dept Gastroenterol, Fukuoka, Japan
[12] Shizuoka Canc Ctr, Dept Colon & Rectal Surg, Shizuoka, Japan
[13] Univ Tokyo, Grad Sch Med, Hepatobiliary Pancreat Surg Div, Artificial Organ & Transplantat Div,Dept Surg, Tokyo, Japan
[14] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Tokyo, Japan
[15] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan
[16] Hiroshima Univ Hosp, Gastroenterol & Metab, Hiroshima, Japan
[17] Kyoto Univ, Dept Surg, Kyoto, Japan
[18] Kagawa Univ, Dept Clin Oncol, Fac Med, Takamatsu, Kagawa, Japan
[19] Nagoya Univ, Div Surg Oncol, Dept Surg, Grad Sch Med, Nagoya, Aichi, Japan
[20] Natl Def Med Coll, Dept Surg, Saitama, Japan
[21] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[22] Int Univ Hlth & Welf, Chemotherapy Res Inst, Dept Hemodialysis & Surg, Ichikawa, Japan
[23] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan
[24] Shinko Hosp, Diagnost Pathol Ctr, Kobe, Hyogo, Japan
[25] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo, Japan
[26] Tohoku Med & Pharmaceut Univ, Dept Hlth Adm & Policy, Sendai, Miyagi, Japan
[27] Aomori Prefectural Cent Hosp, Dept Surg, Ctr Canc, Aomori, Japan
[28] Japanese Red Cross Kanazawa Hosp, Dept Surg, Kanazawa, Ishikawa, Japan
[29] Misawa City Hosp, CEO, Misawa, Japan
[30] Kochi Hlth Sci Ctr, Div Clin Oncolgy, Kochi, Japan
[31] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[32] Hiroshima Univ Hosp, Dept Endoscopy, Hiroshima, Japan
[33] Kurume Univ, Div GI Endoscopy, Sch Med, Fukuoka, Japan
[34] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[35] Lib SEIREI SAKURA Citizen Hosp, Sakura, Chiba, Japan
[36] Tochigi Canc Ctr, Dept Surg, Utsunomiya, Tochigi, Japan
[37] Koujinkai Daiichi Hosp, Tokyo, Japan
关键词
Colorectal cancer; Guideline; Surgery; Chemotherapy; Endoscopy; Radiotherapy; PHASE-III TRIAL; TOTAL MESORECTAL EXCISION; FLUOROURACIL PLUS LEUCOVORIN; INTERVAL HEPATIC RESECTION; SINGLE-AGENT PANITUMUMAB; FRAIL ELDERLY-PATIENTS; LYMPH-NODE METASTASIS; HIGH-DOSE LEUCOVORIN; INTENSIVE FOLLOW-UP; WILD-TYPE KRAS;
D O I
10.1007/s10147-017-1101-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many new treatment methods have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2016 for the treatment of colorectal cancer (JSCCR Guidelines 2016) were prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines were prepared by consensus reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches, and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2016.
引用
收藏
页码:1 / 34
页数:34
相关论文
共 147 条
  • [1] Developing strategies for liver metastases from colorectal cancer
    Adam, Rene
    [J]. SEMINARS IN ONCOLOGY, 2007, 34 (02) : S7 - S11
  • [2] Aihara M, 2010, GRADE SYSTEM CLIN PR
  • [3] Allen MS, 1999, J THORAC CARDIOV SUR, V117, P75
  • [4] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [5] GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
    Andrews, Jeff
    Guyatt, Gordon
    Oxman, Andrew D.
    Alderson, Phil
    Dahm, Philipp
    Falck-Ytter, Yngve
    Nasser, Mona
    Meerpohl, Joerg
    Post, Piet N.
    Kunz, Regina
    Brozek, Jan
    Vist, Gunn
    Rind, David
    Akl, Elie A.
    Schuenemann, Holger J.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (07) : 719 - 725
  • [6] GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength
    Andrews, Jeffrey C.
    Schuenemann, Holger J.
    Oxman, Andrew D.
    Pottie, Kevin
    Meerpohl, Joerg J.
    Coello, Pablo Alonso
    Rind, David
    Montori, Victor M.
    Brito, Juan Pablo
    Norris, Susan
    Elbarbary, Mahmoud
    Post, Piet
    Nasser, Mona
    Shukla, Vijay
    Jaeschke, Roman
    Brozek, Jan
    Djulbegovic, Ben
    Guyatt, Gordon
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (07) : 726 - 735
  • [7] [Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship
  • [8] [Anonymous], CAS TREAT 2003 2004
  • [9] [Anonymous], 2011, CAS TREAT 2000 2002, V29
  • [10] Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B
    Asaka, Shin-ichi
    Arai, Yoshiko
    Nishimura, Yoji
    Yamaguchi, Kensei
    Ishikubo, Tsutomu
    Yatsuoka, Toshimasa
    Tanaka, Yoichi
    Akagi, Kiwamu
    [J]. CARCINOGENESIS, 2009, 30 (03) : 494 - 499